|  |  |
| --- | --- |
|  | **Advanced Microneedling in Aesthetic Medicine**  Release Date: 1/1/2023  Review & Renewal Date: 1/1/2024  Reviewed & Renewed Date: 1/17/2025  Expiration Date: 12/31/2025 |

**Activity Overview**

This activity reviews the data supporting microneedling monotherapy and combinations: mechanism of action, application in different disease states, and risk profiles. It also discusses the most effective and safest integration into clinical practice including advanced skills demonstrations as well as pearls for success based on expert experience and recommendations.

**Target Audience**

This activity is intended to meet the needs of physicians, physician assistants, nurse practitioners, and nurses.

**Learning Objectives**Upon completion of the educational activity, participants should be able to:

* Discuss the mechanism of action and biologic changes in the skin responsible for effects seen post-microneedling.
* Review the safety and efficacy of microneedling monotherapy in scarring, rejuvenation, pigmentary disorders, and striae.
* Compare the safety and efficacy of microneedling to other resurfacing and rejuvenation therapies.
* Review the safety and efficacy of microneedling combination therapy.
* Utilize microneedling with and without PRP therapy when treating patients for acne or surgical scarring, rejuvenation, and striae.

**Method of Participation**   
In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon completion of the post-test and online evaluation/claim credit form. If you have questions about this CE activity, please contact AKH Inc. at [lritley@akhcme.com](mailto:lritley@akhcme.com) .

|  |  |
| --- | --- |
|  | **CE Credit Provided by AKH Inc., Advancing Knowledge in Healthcare.** |

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and REVIVE™ Advanced Training Consultants. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians**  
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 3.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses**

Credit being awarded: 3.0 ANCC contact hours

**Physician Associate**

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. Approval is valid until 12/31/2025. PAs should only claim credit commensurate with the extent of their participation.

**Nurse Practitioners**  
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and REVIVE™ Advanced Training Consultants. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 3.0 contact hours which includes 3.0 hours of pharmacology.

**Commercial Support**This activity is supported from an independent medical education grant from Crown Aesthetics.

**Disclosure**

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

|  |  |  |
| --- | --- | --- |
| **DISCLOSURES** | | |
| **Name** | **Relationship** | **Commercial Interest** |
| Amelia Hausauer, MD (faculty) | Advisor | Alastin Skincare , Allergan Aesthetics, Crown Aesthetics, Galderma, Pelage Pharmaceuticals, Turn Biotechnologies |
|  | Consultant  Individual stocks and stock options  Royalties or patent beneficiary  Speaker | Alastin Skincare , Allergan Aesthetics, Crown Aesthetics, Galderma, Pelage Pharmaceuticals, Revance, Turn Biotechnologies  Pelage Pharmaceuticals  Thieme publishing book royalties  Alastin, Skincare Allergan Aesthetics, Galderma, Revance |
| Dorothy Caputo, MA, BSN, RN - Senior Director of Continuing Education & Compliance | N/A | Nothing to Disclose |
| Bernadette Marie Makar, MSN, NP-C, APRN-C – Nurse Reviewer | N/A | Nothing to Disclose |
| AKH staff and planners | N/A | Nothing to Disclose |
| REVIVE™ staff and planners | N/A | Nothing to Disclose |
| **All of the relevant financial relationships listed for these individuals have been mitigated.** | | |

**Disclaimer**

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

**Disclosure of Unlabeled Use and Investigational Product**

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.